Rahman Ziyaur, Akhtar Sohail, Siddiqui Akhtar, Ciavarella Anthony B, Nguyenpho Agnes, Faustino Patrick J, Khan Mansoor A
1Division of Product Quality and Research Center for Drug Evaluation and Research Food and Drug Administration Maryland, USA.
3Division of Product Quality and Research Center for Drug Evaluation and Research Food and Drug Administration Maryland, USA.
Acta Pharm. 2018 Mar 1;68(1):31-46. doi: 10.2478/acph-2018-0001.
Coumadin® a nd s everal generic products of warfarin s odium (WS) contain the crystalline form (clathrate) in which WS and isopropanol (IPA) are associated in a 2:1 molar ratio. IPA is critical in maintaining the WS crystalline structure. Physicochemical properties of the drug and drug product may change when the crystalline drug transforms to amorphous form. A headspace-gas chromatography (HS-GC) method was developed and validated for IPA determination in the WS drug product. n-propanol (NPA) was used as internal standard and the method was validated for specificity, system suitability, linearity, accuracy, precision, range, limits of detection and quantification, and robustness. The method was specific, with good resolution between IPA and NPA peaks. Chromatographic parameters (retention time, IPA/NPA area ratio, tailing factor, theoretical plates, USP symmetry, capacity factor, selectivity and resolution) were consistent over three days of validation. The analytical method was linear from 2-200 μg mL-1 (0.1- 10 % IPA present in the drug product). LOD and LOQ were 0.1 and 2 μg mL-1, respectively. Accuracy at low (2 μg mL-1) and high (200 μg mL-1) IPA concentrations of the calibration curve was 103.3-113.3 and 98.9-102.2 % of the nominal value, resp. The validated method was precise, as indicated by the RSD value of less than 2 % at three concentration levels of the calibration curve. The method reported here was utilized to determine accurately and precisely the IPA content in in-house formulations and commercial products. In summary, IPA determination by HS-GC provides an indirect measure of WS crystallinity in the drug product. Nevertheless, it should be confirmed by another analytical method since IPA from the drug substance is not distinguishable from IPA that may be present outside the drug crystals in a dosage form when prepared by wet granulation with IPA.
华法林钠片(Coumadin®)及几种华法林钠(WS)的仿制药含有晶型(包合物),其中WS与异丙醇(IPA)以2:1的摩尔比结合。IPA对于维持WS的晶体结构至关重要。当结晶药物转变为无定形形式时,药物及药品的物理化学性质可能会发生变化。开发并验证了一种顶空气相色谱(HS-GC)法用于测定WS药品中的IPA。正丙醇(NPA)用作内标,该方法在特异性、系统适用性、线性、准确度、精密度、范围、检测限和定量限以及稳健性方面进行了验证。该方法具有特异性,IPA和NPA峰之间具有良好的分离度。在三天的验证过程中,色谱参数(保留时间、IPA/NPA面积比、拖尾因子、理论塔板数、USP对称性、容量因子、选择性和分离度)保持一致。该分析方法在2 - 200 μg mL-1(药品中IPA含量为0.1 - 10%)范围内呈线性。检测限和定量限分别为0.1和2 μg mL-1。校准曲线在低(2 μg mL-1)和高(200 μg mL-1)IPA浓度下的准确度分别为标称值的103.3 - 113.3%和98.9 - 102.2%。如校准曲线三个浓度水平下RSD值小于2%所示,验证后的方法具有精密度。本文报道的方法用于准确测定自制制剂和市售产品中的IPA含量。总之,通过HS-GC测定IPA可间接衡量药品中WS的结晶度。然而,由于原料药中的IPA与制剂湿法制粒时可能存在于药物晶体之外的IPA无法区分,因此应通过另一种分析方法进行确认。